Evidence map›Paper›PMID 27292222›Full record

ReviewKidney international2016

Nanomedicines for kidney diseases.

Ryan M Williams, Edgar A Jaimes, Daniel A Heller

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Advances in Nano-Immunomodulatory Systems for the Treatment of Acute Kidney Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Charge barriers in the kidney elimination of engineered nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ryan M WilliamsMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Edgar A JaimesMemorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA. Electronic address: jaimese@mskcc.org.
Daniel A HellerMemorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA. Electronic address: hellerd@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Transient Metabolite Detection for Single-Cell Metabolomics and DiagnosticsDP2HD075698 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2012 to 2012
$2.7M
NCI NIH HHS P30 CA008748NICHD NIH HHS DP2 HD075698
6 · The paper itself

Abstract

Nanomedicines have been the subject of great interest for the treatment, diagnosis, and research of disease; however, few specifically address kidney disorders. Nanotechnology can confer significant benefits to medicine, such as the targeted delivery of drugs to specific tissues. Nanomedicines in the clinic have increased drug solubility, reduced off-target side effects, and provided novel diagnostic tools. There is an increasing cohort of nanomaterials that may have implications for kidney disease. Here, we review nanomaterial properties that are potentially applicable to kidney research and therapy, and we highlight clinical areas of need that may benefit from kidney nanomedicines.

Indexed as

Drug Delivery SystemsHumansKidneyKidney DiseasesNanomedicineNanoparticlesRenal Eliminationdiagnosticsdrug developmentimagingnanoparticlestheranosticstherapeutics

Identifiers

PMID27292222
PMCPMC5064150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.